Dermatológia pre prax 1/2010

Acne-like rash and another skin toxicities associated with administration of HER1/EGFR inhibitors

The use of human epidermal growth factor receptor (HER1/EGFR) inhibitors, such as erlotinib, cetuximab and panitumumab is often accompanied by the development of a characteristic spectrum of skin toxicities. Although these toxicities rarely are life threatening, they can cause physical and emotional discomfort for patient and care staff. When they are considerable, it is sometimes necessary to change before planned treatment regimen. Skin rash is a marker of efficacy of the treatment with HER1/EGFR inhibitors, survival is significantly better in patients with superior degree of skin toxicities, than in patients without them. To recognize such type of reactions and appropriate therapeutic management is assumption for successfully targeted therapy for further oncological diseases.

Keywords: acne-like rash, another skin toxicities, HER1/EGFR inhibitors, targeted oncological treatment